Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Autolus Therapeutics plc

Market Cap 415M 359M 330M 309M 580M 39.46B 589M 3.9B 1.52B 19.21B 1.56B 1.53B 66.51B P/E Ratio 2026 *
-1.73x
P/E Ratio 2027 * -2.39x
Enterprise Value 376M 324M 299M 280M 524M 35.71B 533M 3.53B 1.38B 17.38B 1.41B 1.38B 60.18B EV / Sales 2026 *
2.91x
EV / Sales 2027 * 2.4x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 week+1.96%
Current month-16.58%
1 month-8.77%
3 months+8.33%
6 months-3.11%
Current year-21.61%
1 week 1.38
Extreme 1.38
1.64
1 month 1.38
Extreme 1.38
1.95
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.7
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
8
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2014-08-31
Chief Executive Officer 61 2016-02-29
Director of Finance/CFO 56 2023-08-06
Director TitleAgeSince
Chairman 61 2014-09-30
Director/Board Member 78 2014-07-31
Director/Board Member 71 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
03-17Other

U.S. CCO & Country Gen Manager

761,000 0.4581%
03-17Other

Director

240,000 0.1445%
03-17Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.96%-26.42%-45.64% 415M
+0.11%-3.67%+15.66%-20.23% 62.28B
+1.44%+5.33%+68.19%+222.27% 60.59B
+0.70%+29.50%+29.50%+29.50% 39.55B
+0.26%+9.80%-54.99%-65.15% 36.8B
+0.05%+2.41%+53.12%-34.32% 29.53B
+0.65%+6.01%+60.19%+75.19% 21.68B
+0.54%+5.21%+87.14%-61.00% 19.8B
+4.80%-0.20%-5.27%+115.05% 16.96B
+0.18%-1.66%+54.11%+100.91% 16.16B
Average +0.87%+2.99%+28.12%+31.66% 30.38B
Weighted average by Cap. +0.80%+2.98%+31.68%+45.92%

Financials

2026 *2027 *
Net sales 129M 112M 103M 96.22M 180M 12.28B 183M 1.21B 473M 5.98B 485M 474M 20.69B 193M 167M 154M 144M 270M 18.38B 274M 1.82B 709M 8.95B 726M 710M 30.98B
Net income -246M -212M -196M -183M -343M -23.35B -348M -2.31B -900M -11.37B -922M -902M -39.35B -192M -166M -153M -143M -268M -18.24B -272M -1.8B -703M -8.88B -720M -705M -30.75B
Net Debt -39.53M -34.14M -31.46M -29.45M -55.19M -3.76B -56.05M -372M -145M -1.83B -148M -145M -6.33B 48.41M 41.81M 38.53M 36.07M 67.59M 4.6B 68.64M 455M 177M 2.24B 182M 178M 7.76B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26-06-12 1.560 $ 0.00% 1,019,732
26-06-11 1.560 $ +5.41% 923,485
26-06-10 1.480 $ +1.37% 890,705
26-06-09 1.460 $ 0.00% 1,567,458
26-06-08 1.460 $ -4.58% 1,536,906
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.560USD
Average target price
8.711USD
Spread / Average Target
+458.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!